Literature DB >> 31496582

Hyperthermic Intraperitoneal Chemotherapy as a Treatment for Epithelial Ovarian Cancer.

Mohamed Ibrahim Fahim1, Omaya Abdelhamid Nassar1, Osman Mohamed Mansour2, Abdelmaksoud Mohamed Ali1, Ahmed-Mostafa Mahmoud1, Nesreen Hassan Hafez3, Rasha Mahmoud Allam4, Amr Kamal1, Mohamed Ghareeb2.   

Abstract

Treatment by cytoreductive surgery (CRS) and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has been an option for selected patients with peritoneal carcinomatosis. This study aims to evaluate the impact of HIPEC in epithelial ovarian cancer (EOC). A retrospective observational cohort study including 48 EOC patients treated and followed up between 2012 and 2016. Thirty-seven cases were treated by CRS only, while 11 cases were treated by CRS and HIPEC. The study was performed at National Cancer Institute (NCI)-Cairo University. There was no statistically significant difference regarding overall survival or disease-free survival between the group of EOC patients treated by CRS only and the one treated by CRS and HIPEC. Presence of ascites and histological types (serous/non-serous) were the significant independent variables related to overall survival. Presence of ascites was the only independent variable associated with a significant relation to disease-free survival. No statistically significant impact of HIPEC in treatment of EOC was found in this study.

Entities:  

Keywords:  Cytoreductive surgery (CRS); Epithelial ovarian cancer (EOC); Hyperthermic intraperitoneal chemotherapy (HIPEC); Peritoneal cancer index (PCI); Peritoneal carcinomatosis

Year:  2019        PMID: 31496582      PMCID: PMC6708051          DOI: 10.1007/s13193-018-0867-y

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  7 in total

Review 1.  Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.

Authors:  Y R Huo; A Richards; W Liauw; D L Morris
Journal:  Eur J Surg Oncol       Date:  2015-09-25       Impact factor: 4.424

2.  Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.

Authors:  Israel Manzanedo; Fernando Pereira; Estíbalitz Pérez-Viejo; Ángel Serrano; Miguel Hernández-García; Beatriz Martínez-Torres; Cristina Rihuete-Caro; Julia Calzas; Margarita Cueto
Journal:  Minerva Ginecol       Date:  2016-07-14

3.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?

Authors:  L Gonzalez Bayon; M A Steiner; W Vasquez Jimenez; J M Asencio; P Alvarez de Sierra; F Atahualpa Arenas; J Rodriguez del Campo; J L Garcia Sabrido
Journal:  Eur J Surg Oncol       Date:  2013-07-17       Impact factor: 4.424

4.  Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.

Authors:  Pedro Antonio Cascales-Campos; J Gil; E Gil; E Feliciangeli; A González-Gil; J J Parrilla; P Parrilla
Journal:  Ann Surg Oncol       Date:  2014-03-06       Impact factor: 5.344

5.  Ovarian cancer.

Authors:  Bryan T Hennessy; Robert L Coleman; Maurie Markman
Journal:  Lancet       Date:  2009-09-28       Impact factor: 79.321

6.  Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients.

Authors:  Rene Warschkow; Ignazio Tarantino; Jochen Lange; Sascha A Müller; Bruno M Schmied; Michael Zünd; Thomas Steffen
Journal:  Patient Saf Surg       Date:  2012-06-15

7.  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

Authors:  Willemien J van Driel; Simone N Koole; Karolina Sikorska; Jules H Schagen van Leeuwen; Henk W R Schreuder; Ralph H M Hermans; Ignace H J T de Hingh; Jacobus van der Velden; Henriëtte J Arts; Leon F A G Massuger; Arend G J Aalbers; Victor J Verwaal; Jacobien M Kieffer; Koen K Van de Vijver; Harm van Tinteren; Neil K Aaronson; Gabe S Sonke
Journal:  N Engl J Med       Date:  2018-01-18       Impact factor: 91.245

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.